Printer Friendly

IMMULOGIC APPOINTS SENIOR DIRECTOR, REGULATORY AFFAIRS

 IMMULOGIC APPOINTS SENIOR DIRECTOR, REGULATORY AFFAIRS
 CAMBRIDGE, Mass., Jan. 13 /PRNewswire/ -- ImmuLogic Pharmaceutical


Corporation (NASDAQ: IMUL) today announced the appointment of Martha J. Carter to the newly created position of senior director, regulatory affairs.
 "Martha Carter brings to ImmuLogic over 10 years of biopharmaceutical and pharmaceutical regulatory affairs experience," said Richard E. Bagley, president and CEO of ImmuLogic. "We welcome her to our management team and look forward to many contributions as we prepare to begin the clinical development of our ALLERVAX(tm) allergy therapeutics, led by our CATVAX(tm) product to treat cat allergies." Bagley added that Ms. Carter's appointment is part of the company's program to expand its biopharmaceutical development capabilities as the ALLERVAX product commercialization program advances.
 Ms. Carter joins ImmuLogic from Serono Laboratories, Inc., where she served as vice president of regulatory affairs. Prior to Serono she served in regulatory affairs capacities at Fisons Corporation. Ms. Carter holds a Bachelor of Arts in Biology cum laude from Northeastern University, and did further study in therapeutics at the Massachusetts College of Pharmacy and Allied Health Sciences.
 ImmuLogic is developing products to treat allergies and autoimmune diseases. The company's technical approach is based upon proprietary discoveries and an advanced understanding of the molecular events controlling the human immune system. ImmuLogic is developing a family of ALLERVAX products to treat allergic diseases and the company has recently announced an agreement with Marion Merrell Dow Inc. to collaborate on the worldwide commercialization of these products. The company is also collaborating with Merck & Co. to develop treatments for Type I diabetes and rheumatoid arthritis.
 -0- 1/13/92
 /CONTACT: Janet C. Bush, vice president, finance and administration of ImmuLogic Pharmaceuticals Corporation, 617-494-0060/
 (IMUL) CO: ImmuLogic Pharmaceutical Corporation ST: Massachusetts IN: MTC SU: PER


DD-SD -- NE008 -- 9025 01/13/92 10:47 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 13, 1992
Words:301
Previous Article:SHAW INDUSTRIES REPORTS RESULTS
Next Article:A CRAY RESEARCH SUPERCOMPUTER ACQUIRED BY PREMIER GERMAN ENERGY RESEARCH LABORATORY
Topics:


Related Articles
JESS L. BELSER RESIGNS FROM IMMULOGIC BOARD OF DIRECTORS
BIOGEN ANNOUNCES RESIGNATION OF DR. ROBERT J. GERETY, VICE PRESIDENT -DEVELOPMENT OPERATIONS
BIOGEN ANNOUNCES NEW MANAGEMENT APPOINTMENTS
Dyax Corp. Names Shirish Hirani Vice President of Program Management, Research Division

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters